128 related articles for article (PubMed ID: 38100400)
1. Concerns That May Limit the Utility of Zuranolone.
Prasad V; Allely D
JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
[TBL] [Abstract][Full Text] [Related]
2. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
Barnes KN; Vogl CM; Nelson LA
Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
[TBL] [Abstract][Full Text] [Related]
3. New depression drug zuranolone one step closer to FDA ruling.
Carvalho T
Nat Med; 2023 May; 29(5):1032-1033. PubMed ID: 37041352
[No Abstract] [Full Text] [Related]
4. A Fast-Acting Pill Received Approval for Postpartum Depression-Is It a Game Changer?
Rubin R
JAMA; 2023 Sep; 330(10):902-904. PubMed ID: 37610758
[TBL] [Abstract][Full Text] [Related]
5. Zuranolone: First Approval.
Heo YA
Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
[TBL] [Abstract][Full Text] [Related]
6. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
[TBL] [Abstract][Full Text] [Related]
8. Food and Drug Administration-Approved Treatments for Acute Bipolar Depression: What We Have and What We Need.
Citrome L
J Clin Psychopharmacol; 2020; 40(4):334-338. PubMed ID: 32639285
[No Abstract] [Full Text] [Related]
9. New Drugs & Indications for 2017: The Year in Review.
J Psychosoc Nurs Ment Health Serv; 2018 Jan; 56(1):19. PubMed ID: 29328352
[No Abstract] [Full Text] [Related]
10. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.
Kim J; Farchione T; Potter A; Chen Q; Temple R
N Engl J Med; 2019 Jul; 381(1):1-4. PubMed ID: 31116916
[No Abstract] [Full Text] [Related]
11. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
12. Esketamine for treatment resistant depression.
Jauhar S; Morrison P
BMJ; 2019 Sep; 366():l5572. PubMed ID: 31548292
[No Abstract] [Full Text] [Related]
13. Thinking outside the (black) box: antidepressants, suicidality, and research synthesis.
Greenhouse JB; Kelleher KJ
Pediatrics; 2005 Jul; 116(1):231-3. PubMed ID: 15995059
[No Abstract] [Full Text] [Related]
14. Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials.
Preskorn SH
J Psychiatr Pract; 2021 Mar; 27(2):115-120. PubMed ID: 33656817
[TBL] [Abstract][Full Text] [Related]
15. Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
Arnaud A; Bonthapally V
J Affect Disord; 2022 Mar; 301():445-447. PubMed ID: 35032505
[No Abstract] [Full Text] [Related]
16. Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
Wesevich A; Ratain MJ
JAMA Oncol; 2023 Nov; 9(11):1489-1490. PubMed ID: 37651126
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
Roman MW; Wilkinson SM
Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751
[TBL] [Abstract][Full Text] [Related]
18. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
[TBL] [Abstract][Full Text] [Related]
19. Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
Ten Doesschate F; van Waarde JA; van Wingen GA
J Affect Disord; 2022 Sep; 313():149-150. PubMed ID: 35780962
[No Abstract] [Full Text] [Related]
20. Establishing the real cost of depression.
Sheehan DV
Manag Care; 2002 Aug; 11(8 Suppl):7-10; discussion 21-5. PubMed ID: 12233202
[No Abstract] [Full Text] [Related]
[Next] [New Search]
